Coronary Stents Market Explore Future Growth Top key Players are Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems, Kyoto Medical Planning Co., Ltd

Increasing product launches coupled with increasing geographical approval in drug eluting coronary stents is propelling growth of the coronary stents market. For instance, in May 2018, Abbott received the U.S. FDA approval for XIENCE Sierra, the new generation of everolimus-eluting coronary stent. The XIENCE received approval from the Japan’s regulatory body in April 2018, and CE mark from European regulatory bodies in 2017. Furthermore, companies are also evaluating and launching products with novel material, such as with metal like cobalt chromium and fully biodegradable stents. For instance, in 2017, Biotronik received FDA approval for PRO-Kinetic energy cobalt chromium-based bare metal coronary stent system to treat coronary artery blockage. However, coronary stents market is also subjected to the factors such as stringent regulatory approval policies for the interventional devices and medical complications such as restenosis and thrombosis, which are expected to restrain coronary stents market growth.

Request Sample Copy Of This Report: www.coherentmarketinsights.com/insight/request-sample/2031

Coronary stents are small wired mesh-like medical interventional devices used for treatment of narrowed arteries. Increasing incidence of coronary blockage and changes in lifestyle from physically active to sedentary lifestyle, in turn is increasing cholesterol accumulation, and in turn aiding the coronary stents market growth. For instance, according to World Health Organization (WHO) 2017 survey, the global prevalence of obesity increased by three times between 1975 and 2016.

The trajectory growth in the coronary stents market can be attributed to increasing number of product launches in the market. Intense competition and pricing pressure is compelling manufacturers to develop cost-effective and innovative stents in the market.

For instance, in 2017, Medtronic received approval for Onyx drug eluting stents from the U.S. FDA for the treatment of coronary artery disease in adults. In the same year, company also received approval for cobalt chromium coronary stent system, known as Pro-Kinetic energy stents after BIOHELIX-I studies.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2031

Furthermore, in 2017, Cordis launched two products: the Tryton Side Branch Stent and Medinol’s NIRxcell, a cobalt-chromium bare metal stent (BMS) under comprehensive interventional cardiology portfolio at 29th Transcatheter Cardiovascular Therapeutics Symposium. Such product launches in symposiums and conferences are expected to highlight the product and its features to healthcare professionals and distributors, in turn aiding in increasing the customer base of the company.

Mergers and acquisition by key players are further augmenting the coronary stents market growth with major players enhancing their market share and leveraging the strengths of the acquired company. For instance, in February 2018, Stentys confirms its rights to acquire MINVASYS, a France-based cardiovascular disorder solutions specialist, to accelerate its development and to establish as a benchmark in interventional cardiology market.

Major players operating in the coronary stents market include Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems, Kyoto Medical Planning Co., Ltd., QualiMed, Elixir Medical Corporation, ENDOCOR GmbH, BIOTRONIK SE & Co. KG, Amaranth Medical, Inc. and Arterial Remodeling Technologies SA

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2031

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.